Free Trial
NASDAQ:PTPI

Petros Pharmaceuticals 4/1/2024 Earnings Report

Petros Pharmaceuticals logo
$0.03 +0.00 (+0.35%)
As of 03:59 PM Eastern

Petros Pharmaceuticals EPS Results

Actual EPS
-$54.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Petros Pharmaceuticals Revenue Results

Actual Revenue
($0.36) million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Petros Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Petros Pharmaceuticals Earnings Headlines

This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
Petros Pharmaceuticals, Inc. (PTPI) - Yahoo Finance
See More Petros Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Petros Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Petros Pharmaceuticals and other key companies, straight to your email.

About Petros Pharmaceuticals

Petros Pharmaceuticals (NASDAQ:PTPI), a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

View Petros Pharmaceuticals Profile

More Earnings Resources from MarketBeat